Exchange: NYSE·Updated 11:02 AM EDT

GKOS News

News
all
press releases
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Zacks
Glaukos Stock Gains 36.8% in 6 Months: What's Behind the Rally?
GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.
Zacks
More News
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom's strong margins, G7 15-day rollout and promising pipeline support its growth outlook, but factory ramp-up costs, forex and input-price pressures pose risks.
Zacks
Glaukos Reveals Superior Intraocular Pressure Reduction With Novel Eye Therapy
Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy over standalone cataract surgery.read more...
Benzinga
Glaukos Strengthens Retinal Pipeline Through RevOpsis Licensing Deal
GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.
Zacks
Glaukos Reports Positive Phase 4 Results For IDose TR With Cataract Surgery
(RTTNews) - Friday, Glaukos Corporation (GKOS) announced positive topline results from a Phase 4 study evaluating iDose TR in combination with cataract surgery in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT...
Nasdaq News: Markets
Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose TR in Combination with Cataract Surgery
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical...
Business Wire
Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal
Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOpsis retinal candidate RO-104.read more...
Benzinga
Glaukos Announces Exclusive License Agreement with RevOpsis Therapeutics to Develop and Commercialize RO-104, a First-in-Class Tri-Specific Biologic for Retinal Diseases
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced an exclusive license agreement with RevOpsis Therapeutics, Inc. to develop and...
Business Wire
Glaukos Announces Positive Three-Year Epioxa Results Demonstrating Durable Clinical Outcomes in Keratoconus
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today positive topline results from a long-term Phase 3 extension study (GLK-202-03) evaluating...
Business Wire
Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?
Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.
Zacks

Advertisement|Remove ads.